Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
We’re conducting a 3-minute survey that tracks the mood across the industry — science, finance, hiring and regulation
The new for-profit spinoff from the AI research group FutureHouse has raised a $70 million seed round, the latest funding behind the nascent idea of
Insmed said it is discontinuing work on Brinsupri in a form of chronic rhinosinusitis after the inflammation drug failed a Phase 2b study. The Bridgewater,
The FDA placed a partial hold on Daiichi Sankyo and Merck’s Phase 3 study of a lung cancer drug after the companies paused enrollment for what they called a “higher than anticipated incidence” of deaths …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844